Clinical trial NCT03855540: Atrial Fibrillation in Relationship to Sleep Quality and Plasma Biomarkers
Official title: AFISBIO - Atrial Fibrillation in Relationship to Sleep Quality and Plasma Biomarkers.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation
ECG monitoring
quality of sleep
plasmatic biomarkers
Lead sponsor: Premedix Academy
Sponsor class: OTHER
First posted: 2019-02-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Slovak hospitals and outpatients clinics

Brief summary: A. Compare the plasmatic biomarkers between the cohort with and without AFib.

B. Find sensitive and specific biomarkers that could be used for the diagnostic management of AFib.

C. Compare the quality of sleep between the cohort with and without AFib by the means of sleeping quality questionnaire

Detailed description: AFib is the most common sustained arrhythmia, associated with an increased risk of stroke, heart failure, and mortality. Despite the high prevalence, AFib may be asymptomatic and consequently subclinical. Detection of subclinical AFib is highly challenging as only a minority of the patients is diagnosed during a standard examinations with a 12 - lead ECG or a 24h ECG Holter monitoring. Documented AFib causes 15% of ischemic strokes, however approximately 25% of ischemic strokes is of an unknown etiology. It is believed that undetected subclinical AFib is responsible for these strokes. There is also evidence that asymptomatic AFib is associated with a higher incidence of strokes in comparison to symptomatic AFib.

Due to the fact that the standard ECG examination is not sufficient for AFib detection, various ECG screening methods have been introduced. Intermittent short ECG recording seems to be more effective than 24-hour Holter ECG in the detection of the arrhythmia however, it is not known whether it is superior to the 7 - day ECG Holter monitoring.

Plasmatic biomarkers might be of a paramount importance in the diagnostic management.

Several plasmatic biomarkers were tested to find an association with AFib. Perhaps the most studied ones were the natriuretic peptides that showed to be significantly increased in patients with AFib. Similarly, high sensitivity troponins are elevated in patients with the AFib. Another marker of left atrial stretching and also of ionotropic effects is apelin. Patients with lone AFib showed a significantly decreased levels of this peptide. Conflicting results were shown in studies with inflammatory biomarkers such as high sensitivity CRP Parameters reflecting thrombogenesis were also found to be associated with the arrhythmia. Fibrinogen and fibrin D-dimer were significantly increased in paroxysmal AFib. Finally, in the last years, the circulating micro RNAs emerged as a promising biomarker of AFib, having important function in suppression of messenger RNA responsible for thrombogenesis and ionotropic functions.

The weakness of the mentioned studies is, that the biomarkers were usually tested in patients with a few comorbidities. So, it is not known whether these biomarkers are specific for AFib "per se" or whether they just reflect pathophysiological mechanisms like inflammation, fibrogenesis or left atrium stretching that is also present in other cardiovascular diseases. Furthermore, the AFib cohorts were often not matched with the control groups adding more uncertainty. To clarify these questions, we designed a study where plasmatic biomarkers will be studied in high risk cohort of patients with AFib having several cardiovascular comorbidities. These patients will be subsequently matched with a control group according to the age, gender and the cardiovascular comorbidities.

Similarly, as the continuum of organic changes of the heart from the left ventricular diastolic dysfunction, left atrial dilatation ending with heart failure, there is also "arrhythmology continuum" in patients with arterial hypertension to supraventricular premature contractions via paroxysmal tachycardia of fibrillation up to the permanent atrial fibrillation (AFib). A common etiopathology factor of these disorders is increased sympathetic activity, which together with the catecholamine release during the stress causes arrhythmogenic substrates due to the atrial fibrogenesis. The relation between sleep disorders and the AFib is poorly understood. Micro awakenings during the night increases sympathetic activity and the arterial blood pressure. Other possible mechanism might be the decrease of plasmatic melatonin related to aging. Sleep disorders are linked to the increased heart rate, worsening of the heart rate variability, increased metabolism and body temperature, increased beta EEG activity and activation of the hypothalamic - pituitary - adrenal axis. In patients with arterial hypertension, there is an increased occurrence of premature atrial contractions that is linked to increased risk of AF incidence.

Eligibility criteria: Inclusion Criteria: The specific criteria for inclusion in the study group are:

* Age \>17 years
* Documented, nonvalvular paroxysmal AFib in the duration of more than 6 min. (medical history or ECG monitoring)
* CHA2DS2-VASc score \> 2 for males
* CHA2DS2-VASc score \> 3 for females
* Sinus rhythm at the time of inclusion

The specific criteria for inclusion in the control group are:

* No history of palpitations
* AFib exclusion with the 7 days ECG Holter and ECG event recorder monitoring
* Propensity matching

Exclusion Criteria: Exclusion criteria for both groups:

* Electrical cardioversion less than 7 days prior to inclusion
* Acute coronary syndrome less than 1 month prior to inclusion
* Cardiac surgery less than 3 months prior to inclusion
* Acute or decompensated heart failureat the time of inclusion
* Pregnancy
* Cardiomyopathy
* Alcoholism (≥ 8 drinks/week)
* Thyrotoxicosis
* Renal Disease (Dialysis/ transplant/CrCl \< 0,5ml/s)
* Liver disease (cirrhosis/ transaminase \> 3x ULT/ bilirubin \> 2x ULT)
* Mechanical proshetic valves
* Severe mitral stenosis
* Class I and IV antiarrhythmic drugs usage in last month
* Class III antiarrhythmic drugs usagein last 3 months

Primary outcomes:
measure: Plasmatic biomarkers
timeFrame: Day of inclusion
measure: Quality of sleep
timeFrame: Day of inclusion
Secondary outcomes:
measure: Diagnostic plasmatic biomarker
timeFrame: Day of inclusion
Other outcomes:
Locations:
city: Bratislava
country: Slovakia
facility: Allan Bohm
city: Košice
country: Slovakia
facility: East Slovak Institute of Cardiovascular Diseases
city: Malacky
country: Slovakia
facility: Hospital
city: Nitra
country: Slovakia
facility: University hospital
Study officials:
affiliation: The National Institution of Cardiovascular Diseases
name: Allan Bohm, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Slovak league against hypertension
name: Stefan Farsky, Associate professor
role: PRINCIPAL_INVESTIGATOR
References: